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Abstract
Background: We aimed to estimate the minimally important difference (MID) for interpreting group-level change over time,
both within a group and between groups, for the European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire core 30 (EORTC QLQ-C30) scores in patients with advanced breast cancer.
Methods: Data were derived from two published EORTC trials. Clinical anchors (eg, performance status [PS]) were selected
using correlation strength and clinical plausibility of their association with a particular QLQ-C30 scale. Three change status
groups were formed: deteriorated by one anchor category, improved by one anchor category, and no change. Patients with
greater anchor changes were excluded. The mean change method was used to estimate MIDs for within-group change, and
linear regression was used to estimate MIDs for between-group differences in change over time. For a given QLQ-C30 scale,
MID estimates from multiple anchors were triangulated to a single value via a correlation-based weighted average.
Results: MIDs varied by QLQ-C30 scale, direction (improvement vs deterioration), and anchor. MIDs for within-group change
ranged from 5 to 14 points (improvement) and 14 to 4 points (deterioration), and MIDs for between-group change over
time ranged from 4 to 11 points and from 18 to 4 points. Correlation-weighted MIDs for most QLQ-C30 scales ranged from
4 to 10 points in absolute values.
Conclusions: Our findings aid interpretation of changes in EORTC QLQ-C30 scores over time, both within and between groups,
and for performing more accurate sample size calculations for clinical trials in advanced breast cancer.
Patient-reported outcomes such as health-related quality of life
(HRQOL) are increasingly assessed as important endpoints in
cancer clinical trials. As a result, there is growing interest to im-
prove the interpretation of HRQOL data in cancer clinical trials
(1). It is recognized that interpreting HRQOL scores merely via
statistical significance might be misleading because small
differences in mean scores can be statistically significant, even
when clinical relevance is absent. The minimally important dif-
ference (MID) approach aids interpreting differences and
changes in HRQOL scores as clinically meaningful (2–7). MID can
be defined as the smallest change in a HRQOL score that is per-
ceived as “important” by a patient or by a third party (eg, a
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clinician), which may indicate a change in the patient’s man-
agement (2).
MIDs are commonly estimated using anchor-based and
distribution-based methods (7). Anchor-based methods express
differences or change in HRQOL scores using other familiar vari-
ables that have clinical relevance (3,7–9) or to patient and/or
physician-derived ratings of change in the specific domain (4–
6). Distribution-based methods use the statistical distribution of
HRQOL scores (eg, SD criteria or SEM) and are considered as sup-
portive evidence to anchor-based methods (10).
This study focused on interpreting the European
Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire core 30 (EORTC QLQ-C30) in patients with ad-
vanced breast cancer. Guidelines for interpreting the QLQ-C30
were initially published by King (3) and Osoba et al. (4). King (3)
evaluated published evidence about differences in QLQ-C30
scores between groups for multiple cancer sites and clinical
anchors and found that the score range for small, moderate,
and large effects differed between the scales of the QLQ-C30.
Osoba et al. (4) provided thresholds for interpreting small (5 to
10 points), moderate (10 to 20 points), and large changes (>20
points) in QLQ-C30 scores using a global rating of change in
metastatic breast and small-cell lung cancer patients. Based on
King (3) and Osoba et al. (4), mean differences no less than 10
points are widely regarded as clinically meaningful for the QLQ-
C30 in randomized clinical trials (11). However, recent guide-
lines revealed that MIDs can differ by QLQ-C30 scale, direction
of change (improvement vs deterioration), and settings (5, 6),
rendering a widely applicable rule for MIDs highly unlikely. We
therefore need to gather further empirical evidence on patterns
of MIDs across QLQ-C30 scales and disease sites (12).
This study examined MIDs for group-level change in HRQOL
scores over time. In contrast to Osoba et al. (4), we used avail-
able clinical anchors in the database. Furthermore, the guide-
lines of King (3) and Cocks et al. (5, 6) were based on meta-
analyses of published studies, pooling across cancer sites,
whereas this study used individual patient data from archived
trials.
Methods
Data Description
Data were derived from two published phase III EORTC trials.
Trial 1 assessed the clinical benefit of a dose-intensive anthra-
cycline-based regimen compared with standard treatment in
women with locally advanced breast cancer and enrolled 448
patients (13). Trial 2 compared a combination of doxorubicin
and paclitaxel vs doxorubicin and cyclophosphamide as first-
line chemotherapy in advanced (metastatic) breast cancer and
enrolled 275 patients (14). Both trials assessed HRQOL using the
QLQ-C30 at baseline, during treatment, and at several follow-up
time points after the end of treatment.
The EORTC QLQ-C30
The EORTC QLQ-C30 comprises 30 items, 24 of which are aggre-
gated into 9 multi-item scales: 5 functioning scales (physical,
role, cognitive [CF], emotional, and social); 3 symptom scales
(fatigue, pain, and nausea and/or vomiting); and 1 global health-
status scale. The remaining six single items assess symptoms
of dyspnea, appetite loss (AP), sleep disturbance, constipation,
diarrhea, and financial impact. Both trials used version 2 of the
QLQ-C30, with standard scoring applied to the scales (15). For
consistency in signs, all scales were scored such that 0 repre-
sents the worst possible score and 100, the best possible score.
Financial impact was omitted from the analysis because suit-
able anchors were not available.
Clinical Anchor
Anchors were selected from variables that were available in the
trial datasets (eg, physician examinations and common termi-
nology criteria for adverse events [CTCAE]). Anchors were se-
lected for each HRQOL scale based on correlation strength.
Spearman rank, polyserial, or polychoric correlation was used,
depending on the distribution of the pair of variables. Anchors
with correlations no less than 0.30 were prioritized (10), and
where achievable, anchors with much stronger correlations
were targeted. The retained anchors were further verified for
clinical plausibility by a panel of six breast cancer and/or
HRQOL experts to avoid spurious findings. Multiple anchors
could be selected for each HRQOL scale (12).
For trial 1, the retained anchors comprised 1) World Health
Organization PS, scored between 0 (completely active with no
limitations) and 4 (bedbound); and 2) four CTCAEs (nausea, vom-
iting, fatigue, and alopecia), graded between 0 (no toxicity) to 4
(life-threatening). The only anchor retained for trial 2 was the PS.
Definition of Clinical Change Groups
Three clinical change status groups (CCG) were defined: deterio-
ration (worsened by 1 anchor category), stable (no change in an-
chor category), and improvement (improved by 1 anchor
category). In order not to overestimate the MIDs, change scores
no less than a 2-point change in anchor categories were ex-
cluded from datasets used to estimate MIDs because they were
considered to be above the “minimal” expected change.
Statistical Analysis
Anchor-Based Methods
Change scores of HRQOL scale and anchor pairs were computed
across all pairwise time points and combined to provide suffi-
cient data for examining clinically important changes. For exam-
ple, for a subject measured at time points ta, tb, and tc, change
scores were computed between ta and tb; ta and tc; and tb and tc.
Hence, a subject can contribute multiple change scores, and given
their change scores, subjects can contribute to multiple CCGs.
Only subjects with HRQOL and anchor data for a given pair of
time points contributed to the calculation of change scores. Data
from the two trials were pooled to estimate MIDs.
The mean change method was used to estimate MIDs for
within-group change over time. MIDs for improvement and de-
terioration were computed as the mean HRQOL change scores
for the improvement and deterioration CCGs, respectively. This
is relevant for interpreting change within a single group of
patients, and it is similar to the mean HRQOL change score over
time for a treatment group in a trial. Effect sizes (ESs) were com-
puted within each CCG by dividing the mean of the HRQOL
change scores (derived from all the pairwise time point differen-
ces) by the SD of the HRQOL change scores over all time points.
Only mean changes with an ES no less than 0.2 and less than
0.8 were considered appropriate for inclusion as MIDs. This was
based on Cohen’s (16) recommendations that an ES of 0.2 is
small, 0.5 is moderate, and no less than 0.8 is large. The
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rationale was that ESs less than 0.2 reflect changes that are clin-
ically unimportant, and those no less than 0.8 are obviously
more than minimally important. The difference in change
scores between the improvement (or deterioration) CCG and no
change CCG was compared using analysis of variance (ANOVA).
A linear regression was used to estimate MIDs for differen-
ces between groups in change over time. For a given HRQOL
scale and anchor pair, the outcome variable was the HRQOL
change score, and the covariate was a binary anchor variable
(coded as stable ¼ 0 and improvement ¼ 1 when modeling im-
provement [deteriorated observations were excluded], and
stable ¼ 0 and deterioration ¼ 1 when modeling deterioration
[improved observations were excluded]).
Because change scores were computed across all pairwise
time points, some patients contributed change scores to more
than one CCG and more than one change score to a particular
CCG. We corrected for the association between multiple change
scores contributed by the same patients by specifying a suitable
covariance structure using the generalized estimating equa-
tions (17). The slope parameters for the “improved” and
“deteriorated” covariates correspond to the MID for improve-
ment and deterioration, respectively. This approach is similar
to comparing the mean HRQOL change score over time in a
treatment group to a control group in a trial, which is why these
MIDs are useful for interpreting changes over time between two
distinct groups of patients. Furthermore, we compared the two
trials by adding a “trial” effect in a linear regression model, sep-
arately for improving and deteriorating HRQOL scores. This was
based on the data with PS as the anchor.
Both within-group and between-group MID estimates for a
given HRQOL scale, from multiple anchors, were triangulated to
a single value via a correlation-based weighted average.
Distribution-Based Methods
The SEM, 0.2 SD, 0.3 SD, and 0.5 SD were applied to HRQOL
scores at two time points common to both trials: 1) start of
treatment (t1), time point before or on the first day of treatment,
and 2) end of treatment (t2), last day of protocol treatment.
Test–retest reliability estimates to compute SEM for the QLQ-
C30 were based on Hjermstad et al. (18). All analyses were per-
formed using the SAS software (19).
Results
Table 1 summarizes the demographic and clinical characteris-
tics of patients at baseline. The median follow-up time (in
months) for HRQOL was 5.3 (16.9) for trial 1 and 1.6 (2.8) for trial
2. An overview of the flow of patients through this study is pre-
sented in Supplementary Figure 1 (available online). Cross-
sectional correlations ranged from 0.20 to 0.62 in absolute value,
with a majority of the correlation coefficients being above the
0.30 threshold (7) (Table 2). Correlations between the change
scores ranged from 0.14 to 0.51. At least one suitable anchor
was constructed for 8 of the 14 QLQ-C30 scales that were consid-
ered for this study. The distribution of patients and the number
of change observations across the categories of suitable anchors
are summarized in Supplementary Table 1 (available online).
Table 1. Baseline demographic and clinical characteristics of the patients by study (all patients had advanced breast cancer)
Characteristic Study 10921 No. (%) (N¼ 448) Study 10961 No. (%) (N¼ 275) Total (N¼ 723)
Performance status
0 394 (87.9) 119 (43.3) 513 (71.0)
1 54 (12.1) 133 (48.4) 187 (25.9)
2 0 (0.0) 22 (8.0) 22 (3.0)
Unknown 0 (0.0) 1 (0.4) 1 (0.1)
Number of positive nodes
N0–N1 250 (55.8) 144 (52.4) 394 (54.5)
N2 176 (39.3) 26 (9.5) 202 (27.9)
N4þ 0 (0.0) 51 (18.5) 51 (7.1)
Nx 9 (2.0) 41 (14.9) 50 (6.9)
N3 13 (2.9) 13 (4.7) 26 (3.6)
Country
France 97 (21.7) 41 (14.9) 138 (19.1)
Netherlands 41 (9.2) 42 (15.3) 83 (11.5)
United Kingdom 11 (2.5) 68 (24.7) 79 (10.9)
Poland 78 (17.4) 0 (0.0) 78 (10.8)
Belgium 48 (10.7) 29 (10.5) 77 (10.7)
Canada 68 (15.2) 0 (0.0) 68 (9.4)
Slovenia 22 (4.9) 26 (9.5) 48 (6.6)
Switzerland 28 (6.3) 8 (2.9) 36 (5.0)
Russia 27 (6.0) 0 (0.0) 27 (3.7)
Italy 0 (0.0) 18 (6.5) 18 (2.5)
Israel 0 (0.0) 16 (5.8) 16 (2.2)
South Africa 3 (0.7) 12 (4.4) 15 (2.1)
Portugal 13 (2.9) 0 (0.0) 13 (1.8)
Czech Republic 12 (2.7) 0 (0.0) 12 (1.7)
Spain 0 (0.0) 9 (3.3) 9 (1.2)
Austria 0 (0.0) 6 (2.2) 6 (0.8)
Age, y
Mean (SD) 50.07 (9.68) 52.27 (9.61) —
Range 26.0–79.0 28.0–70.0 —
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Table 3 shows the range of MIDs from the mean change
method (useful for interpreting within-group change over time)
and the linear regression (useful for interpreting between-group
differences in change over time) for each HRQOL scale,
across multiple anchors. Detailed results are presented in
Supplementary Table 2 (available online).
The MIDs varied according to the scale, direction of change
scores (improvement vs deterioration), and anchor (Figure 1).
Estimates were always in the expected direction according to
the anchor (ie, positive vs negative change scores within the im-
provement vs deterioration CCG, respectively). Statistically sig-
nificant differences (ANOVA P < .05) were observed between the
HRQOL change scores for all improvement and deterioration
CCGs vs no change CCG.
MIDs for within-group change (based on the mean-change
method) ranged from 5 to 14 points (improvement) and 14 to 4
points (deterioration), and MIDs for between-group change (based
on the linear regression) ranged from 4 to 11 points and from 18
to 4 points (Table 3). For the majority of the QLQ-C30 scales, the
estimated MIDs ranged from 4 to 10 points in absolute values.
Adding a trial effect to the regression models showed no statisti-
cally significant differences in change scores between the two tri-
als, hence, supporting the combination of the two trials.
The MIDs in Table 3 are summarized to single MID values
per scale in Table 4 and ranged from 4 to 10 points in absolute
values for most HRQOL scales. Table 4 also compares the
anchor-based estimates to the distribution-based estimates at
t1. The distribution-based estimates at t2 for each HRQOL scale
were similar to t1, mostly within a less-than-1-point range. All
anchor-based estimates were no less than 0.2 SD, with most
estimates being less than 0.5 SD. The anchor-based estimates
tended to be closer to both the 0.3 SD and the 1 SEM.
Discussion
This study examined MIDs for interpreting group-level change
of EORTC QLQ-C30 scores over time in patients with advanced
breast cancer. Anchors for each HRQOL scale were selected
Table 2. Correlations over all time points of the EORTC QLQ-C30 scale scores with suitable anchors, and correlations between change scores of
the EORTC QLQ-C30 scales and anchors
Scores Change scores
Scale Anchor n1 (n1R)* Correlation n2 (n2R)* Correlation
PF Performance status 587 (2922) 0.52 548 (8508) 0.30
CTCAE fatigue 355 (2658) 0.30 343 (11102) 0.20
CTCAE vomiting 355 (2656) 0.30 343 (11077) 0.25
RF Performance status 587 (2922) 0.54 547 (8520) 0.20
SF Performance status 594 (2890) 0.34 545 (8390) 0.20
CTCAE fatigue 355 (2630) 0.21 340 (10984) 0.15
CTCAE vomiting 355 (2628) 0.25 340 (10959) 0.20
CF CTCAE fatigue 355 (2638) 0.20 342 (11032) 0.14
QL CTCAE vomiting 355 (2628) 0.39 341 (10892) 0.30
CTCAE nausea 355 (2628) 0.39 341 (10892) 0.30
CTCAE alopecia 355 (2629) 0.39 341 (10914) 0.35
Performance status 585 (2893) 0.32 547 (8351) 0.25
FA Performance status 587 (2915) 0.40 546 (8476) 0.23
CTCAE nausea 355 (2644) 0.21 341 (11 014) 0.15
CTCAE vomiting 355 (2644) 0.22 341 (11 014) 0.16
NV CTCAE nausea 355 (2654) 0.60 343 (11 050) 0.51
CTCAE vomiting 355 (2654) 0.62 343 (11 050) 0.48
AP CTCAE nausea 355 (2621) 0.58 343 (10 816) 0.44
CTCAE vomiting 355 (2621) 0.59 343 (10 816) 0.48
*n1 (n1R) and n2 (n2R) can vary by anchor and EORTC QLQ-C30 scale. AP ¼ appetite loss; CF ¼ cognitive functioning; EORTC QLQ-C30 ¼ European Organisation for
Research and Treatment of Cancer Quality of Life Questionnaire core 30; FA ¼ fatigue; n1 ¼ number of patients with at least 1 matched EORTC QLQ-C30 and an anchor
form; n1R ¼ number of repeated anchor and HRQOL matched forms across all subjects; n2 ¼ number of patients with at least 2 matched EORTC QLQ-C30 and an anchor
form (at least 2 forms are needed to compute change scores); n2R ¼ number of repeated EORTC QLQ-C30 scale and anchor change scores across all subjects; NV ¼ nau-
sea and/or vomiting; PF ¼ physical functioning; QL ¼ global quality of life; RF ¼ role functioning; SF ¼ social functioning.
Table 3. Range of anchor-based MID estimates from the mean
change method and linear regression
Mean change method* Linear regression†
Scale Improvement Deterioration Improvement Deterioration
PF 7 to 10 11 to 10 7 to 9 10 to 8
RF No MID 6 No MID 4
SF 7 to 9 9 to 5 6 to 7 11 to 5
CF 5 4 4 4
QL 10 to 14 11 to 5 8 to 11  13 to 6
FA 8 9 to 7 8 8 to 6
NV No MID 12 No MID 14
AP No MID 14 No MID 18
*The mean change method is useful for interpreting within-group change over
time. The symptom scores were reversed to follow the functioning scales inter-
pretation (ie, 0 represents the worst possible score and 100 the best possible
score); “no MID” is used where no MID estimate is available either because of
the absence of a suitable anchor or ES was either <0.2 or 0.8. All of the ESs for
the no change group were <0.2. AP ¼ appetite loss; CF ¼ cognitive functioning;
ES ¼ effect size; FA ¼ fatigue; MID ¼ minimally important difference; NV ¼ nau-
sea and/or vomiting; PF ¼ physical functioning; QL ¼ global quality of life; RF ¼
role functioning; SF ¼ social functioning.
†The linear regression is useful for interpreting between-group differences in
change over time.
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based on both the correlation strength and the clinical plausibil-
ity. When available, multiple anchors were used per HRQOL
scale to provide some reassurance about the plausibility of the
estimated MIDs. Despite the modest correlation between
anchors and scales change scores, most MID estimates from
multiple anchors were in a narrow range (often<5 points) and
were always in the expected direction according to the anchor
change category.
In agreement with recent findings (5–9), our estimates varied
by HRQOL scale and direction of change (improvement vs dete-
rioration). Similar to Maringwa et al. (8, 9). and Musoro et al. (7),
no systematic differences were observed in the magnitude of
change between deteriorating and improving scores. However,
other studies reported that estimates for deterioration tended
to be larger than those for improvement (6, 20).
We distinguished between MIDs for interpreting the degree
of change within a group (obtained from the mean change
method) and MIDs for interpreting the degree of differences be-
tween groups in within-group change (obtained from linear re-
gression). Interestingly, estimates from both approaches were
often in the same range. For many scales, the MIDs were within
the range of 5–10 points that was suggested by Osoba et al. (4)
Figure 1. Mean change and 95% confidence interval for improvement and deterioration EORTC QLQ-C30 scales, across multiple anchors and averaged across different
time periods. Estimates are available only for scales with at least 1 suitable anchor and with effect size 0.2 and <0.8 within the “deteriorate” and “improve” groups, re-
spectively. These mean change scores are useful for interpreting within-group change over time. AP ¼ appetite loss; CF ¼ cognitive functioning; CTCAE ¼ common ter-
minology criteria for adverse events; deteriorate ¼ worsened by 1 anchor category; EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire Core 30; FA ¼ fatigue; Improve ¼ improved by 1 category; NV ¼ nausea and/or vomiting; PF ¼ physical functioning; QL ¼ global quality of
life; RF ¼ role functioning; SF ¼ social functioning.
Table 4. Summary of anchor-based MIDs for within- and between-group changes compared with distribution-based estimates
Anchor-based MID for
within-group change*
Anchor-based MID for between-groups
difference in change*
Distribution-based
QL scores at t1 (n¼ 415–425)
Scale Improvement Deterioration Improvement Deterioration 0.2 SD 0.3 SD 0.5 SD 1 SEM
PF 9 10 8 9 4.7 7.0 11.7 7.0
RF No MID 6 No MID 4 5.1 7.6 12.7 10.7
SF 8 7 7 8 5.3 7.9 13.1 9.5
CF 5 4 4 4 4.1 6.2 10.3 8.8
QL 12 8 10 10 4.9 7.3 12.2 10.3
FA 8 8 8 7 4.9 7.3 12.2 10.0
NV No MID 11 No MID 14 3.4 5.1 8.5 10.3
AP No MID 14 No MID 18 5.2 7.8 13.1 12.0
*The within-group MIDs (from the mean change method) and the between-group MIDs (from the linear regression) were summarized via weighted averages based on
scale and anchor pair correlation. The symptom scores were reversed to follow the functioning scales interpretation (ie, 0 represents the worst possible score and 100,
the best possible score); “no MID” is used where no MID estimate is available either because of the absence of a suitable anchor or ES was either <0.2 or 0.8. ¼ appetite
loss; CF ¼ cognitive functioning; ES ¼ effect size; FA ¼ fatigue; MID ¼ minimally important difference; n ¼ number of patients; NV ¼ nausea/vomiting; PF ¼ physical
functioning; QL ¼ global quality of life; RF ¼ role functioning; SF ¼ social functioning; t1 ¼ time points for the start of treatment.
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and also observed by Cocks et al. (5, 6), Musoro et al. (7), and
Maringwa et al. (8, 9). However, similar to Cocks et al. (5, 6), we
noticed that the thresholds for some scales were much lower.
For example, MIDs of 4 points were observed for the CF scale.
Musoro et al. (7) also reported MIDs that were as low as 3 points
for the CF scale in patients with malignant melanoma. On the
other hand, similar to Musoro et al. (7), we observed a much big-
ger threshold of 18 points for the AP scale. This reinforces the
evidence that there is no single global standard for clinically
meaningful change, and scale-specific MIDs should therefore be
selected with more caution.
Most often, investigators seeking MIDs would desire simple
guidelines. However, as shown in this article, results are often
varied as a consequence of there being numerous anchors, vari-
ous distribution-based criteria, and multiple HRQOL scales.
Results shown in Figure 1 and Table 3 represent this diversity
because the range of MIDs varies by the different anchors. We
acknowledge that end users may find such a range of options
confusing. So, to provide a single MID value per scale, we further
simplified this by calculating a correlation-weighted average
across multiple anchors. End users can choose to work with ei-
ther the ranges provided in Table 3 or the single values provided
in Table 4, whichever they feel most comfortable with. Most of
the anchor-based estimates were closer to 0.3 SD and 1 SEM
compared to the commonly reported 0.5 (21).
A limitation of this study is that suitable anchors were not
always available, hence, anchor-based MIDs could not be esti-
mated for seven of the EORTC QLQ-C30 scales, which were
omitted in this article Furthermore, the available anchors (PS or
CTCAE grades) relied exclusively on clinical observations or
interpretations. Because the two trials that were used in this
study evaluated chronic delivery of cytotoxic chemotherapy,
clinical anchors such as CTCAE nausea, CTCAE vomiting, and
CTCAE fatigue were reasonable and relevant. The availability of
a pretreatment baseline assessment also allows detecting per-
sistent effects such as alopecia. However, such anchors might
not be relevant in other settings, treatments, or subtypes of
breast cancer. The available anchors were also not necessarily
suitable in all situations. For example, although CTCAE fatigue
met the requirements of a plausible clinical relationship with
the QLQ-C30 fatigue scale, the resulting correlations were too
low (<0.1) to be retained. The low correlation can be explained
by the discrete nature of the CTCAE scale where only a few
high-grade events were scored. Moreover, because of the sub-
jective nature of fatigue, there is likely also misrepresentation
by physicians compared to patients’ ratings as already reported
by Basch et al. (22).This might also explain the potentially in-
flated MID estimates for the AP scale. Also, anchors that are
based on patients’ perspective of change (eg, subjective signifi-
cance questionnaires) were not available in our study.
Nonetheless, it is reassuring to notice the considerable overlap
between our findings and those of Osoba et al. (4), which used
patients’ ratings of change as the anchor. Patients’ self-
assessed ratings across the different QLQ-C30 scales and across
different disease sites are rarely available from retrospective
data sources and would need to be planned as future research
to complement our findings.
Another limitation is that our data originate from
two controlled clinical trials, each with specific selection and
treatment criteria. Although results were consistent between
the trials, extrapolation beyond their specific setting should be
made with caution. A number of articles are available that pro-
vide general guidelines for selecting MIDs for the QLQ-C30
scales (5, 6, 11). For instance, Cocks et al. (6) published MIDs for
interpreting QLQ-C30 change scores over time for all 15 scales
using published results from multiple cancer sites. The MID val-
ues obtained for the eight scales considered in this study were
comparable to those presented by Cocks et al. (6). These increas-
ingly robust guidelines advocate a more nuanced approach to
clinical relevance beyond a single threshold.
In conclusion, our findings can help clinicians and research-
ers interpret the clinical relevance of group-level change of
QLQ-C30 scores over time in patients with advanced breast can-
cer. The fact that MIDs can vary by QLQ-C30 scale and anchor
suggests that we cannot rely on global standards for defining
clinically meaningful change. Finally, our results will also in-
form more accurate sample size calculations for clinical trials in
advanced breast cancer with endpoints that are based on
EORTC QLQ-C30 scales.
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